438 related articles for article (PubMed ID: 27119150)
1. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Mendoza Y; Castillo Mewa J; Martínez AA; Zaldívar Y; Sosa N; Arteaga G; Armién B; Bautista CT; García-Morales C; Tapia-Trejo D; Ávila-Ríos S; Reyes-Terán G; Bello G; Pascale JM
PLoS One; 2016; 11(4):e0154317. PubMed ID: 27119150
[TBL] [Abstract][Full Text] [Related]
2. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
Rhee SY; Blanco JL; Jordan MR; Taylor J; Lemey P; Varghese V; Hamers RL; Bertagnolio S; Rinke de Wit TF; Aghokeng AF; Albert J; Avi R; Avila-Rios S; Bessong PO; Brooks JI; Boucher CA; Brumme ZL; Busch MP; Bussmann H; Chaix ML; Chin BS; D'Aquin TT; De Gascun CF; Derache A; Descamps D; Deshpande AK; Djoko CF; Eshleman SH; Fleury H; Frange P; Fujisaki S; Harrigan PR; Hattori J; Holguin A; Hunt GM; Ichimura H; Kaleebu P; Katzenstein D; Kiertiburanakul S; Kim JH; Kim SS; Li Y; Lutsar I; Morris L; Ndembi N; Ng KP; Paranjape RS; Peeters M; Poljak M; Price MA; Ragonnet-Cronin ML; Reyes-Terán G; Rolland M; Sirivichayakul S; Smith DM; Soares MA; Soriano VV; Ssemwanga D; Stanojevic M; Stefani MA; Sugiura W; Sungkanuparph S; Tanuri A; Tee KK; Truong HM; van de Vijver DA; Vidal N; Yang C; Yang R; Yebra G; Ioannidis JP; Vandamme AM; Shafer RW
PLoS Med; 2015 Apr; 12(4):e1001810. PubMed ID: 25849352
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
4. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
5. Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.
Oumar AA; Jnaoui K; Kabamba-Mukadi B; Yombi JC; Vandercam B; Goubau P; Ruelle J
Acta Clin Belg; 2010; 65(4):242-4. PubMed ID: 20954462
[TBL] [Abstract][Full Text] [Related]
6. Drug Resistance Mutations in a Population Before Antiretroviral Therapy Initiation in Northern South Africa.
Ogola B; Matume ND; Mavhandu-Ramarumo LG; Tebit DM; Bessong PO
AIDS Res Hum Retroviruses; 2022 Mar; 38(3):248-256. PubMed ID: 34107774
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
[TBL] [Abstract][Full Text] [Related]
9. Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.
Almeida FJ; Berezin EN; Rodrigues R; Sáfadi MA; Arnoni MV; Oliveira C; Brígido LF
J Pediatr (Rio J); 2009; 85(2):104-9. PubMed ID: 19319446
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W
PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189
[TBL] [Abstract][Full Text] [Related]
11. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
12. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic.
Kleyn TJ; Liedtke MD; Harrison DL; Lockhart SM; Salvaggio MR; Ripley TL; Rathbun RC
Ann Pharmacother; 2014 Apr; 48(4):470-5. PubMed ID: 24473489
[TBL] [Abstract][Full Text] [Related]
13. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
[TBL] [Abstract][Full Text] [Related]
14. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
15. HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
Avila-Ríos S; García-Morales C; Tapia-Trejo D; Meza RI; Nuñez SM; Parham L; Flores NA; Valladares D; Pineda LM; Flores D; Motiño R; Umanzor V; Carbajal C; Murillo W; Lorenzana I; Palou EY; Reyes-Terán G
PLoS One; 2015; 10(11):e0142604. PubMed ID: 26558396
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia.
Tee KK; Kamarulzaman A; Ng KP
Med Microbiol Immunol; 2006 Jun; 195(2):107-12. PubMed ID: 16404607
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
20. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
